Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122852763 | 12285276 | 3 | F | 2016 | 20160826 | 20160420 | 20160830 | EXP | JP-ABBVIE-16K-087-1607702-00 | ABBVIE | 61.75 | YR | F | Y | 90.00000 | KG | 20160830 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122852763 | 12285276 | 1 | PS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QOW | |||||
| 122852763 | 12285276 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | DOSE INCREASED | Y | UNKNOWN | 125057 | 80 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | QOW | ||||
| 122852763 | 12285276 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | UNKNOWN | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | ||||||
| 122852763 | 12285276 | 4 | C | BETAMETHASONE DIPROPIONATE W/CALCIPOTRIOL | 2 | Topical | 0 | 4 | G | OINTMENT | QD | ||||||||
| 122852763 | 12285276 | 5 | C | MAXACALCITOL | MAXACALCITOL | 1 | Topical | 0 | 1 | G | OINTMENT | QD | |||||||
| 122852763 | 12285276 | 6 | C | WARFARIN POTASSIUM | WARFARIN POTASSIUM | 1 | Oral | 0 | 1.75 | MG | TABLET | QD | |||||||
| 122852763 | 12285276 | 7 | C | FEBUXOSTAT. | FEBUXOSTAT | 1 | Oral | 0 | 10 | MG | TABLET | QD | |||||||
| 122852763 | 12285276 | 8 | C | METILDIGOXIN | METILDIGOXIN | 1 | Oral | 0 | .1 | MG | TABLET | QD | |||||||
| 122852763 | 12285276 | 9 | C | BISOPROLOL FUMARATE. | BISOPROLOL FUMARATE | 1 | Oral | 0 | 5 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122852763 | 12285276 | 1 | Psoriasis |
| 122852763 | 12285276 | 4 | Psoriasis |
| 122852763 | 12285276 | 5 | Psoriasis |
| 122852763 | 12285276 | 6 | Cerebral infarction |
| 122852763 | 12285276 | 7 | Gout |
| 122852763 | 12285276 | 8 | Cardiac failure |
| 122852763 | 12285276 | 9 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122852763 | 12285276 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122852763 | 12285276 | Drug ineffective | |
| 122852763 | 12285276 | Generalised oedema | |
| 122852763 | 12285276 | Paradoxical drug reaction | |
| 122852763 | 12285276 | Psoriasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122852763 | 12285276 | 2 | 20160126 | 20160126 | 0 | |
| 122852763 | 12285276 | 3 | 20160209 | 20160209 | 0 |